R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: A pilot study

Leukemia and Lymphoma

Volumn 49, Issue 6, 2008, Pages 1081-1086

  Visani, Giuseppe ^a   Ferrara, Felicetto ^b   Alesiani, Francesco ^c   Ronconi, Sonia ^d   Catarini, Massimo ^e   D'adamo, Francesca ^a   Guiducci, Barbara ^a   Bernardi, Daniele ^f   Barulli, Sara ^a   Piccaluga, Pierpaolo ^g   Rocchi, Marco ^h   Isidori, Alessandro ^a  

^a SAN SALVATORE HOSPITAL   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c Bartolomeo Eustacchio Hospital   (Italy)

^d MORGAGNI PIERANTONI HOSPITAL   (Italy)

^e Hospital of Macerata   (Italy)

^f Civil Hospital   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h UNIVERSITY OF URBINO   (Italy)

Author keywords

Doxorubicin; Frail patients; Liposomal doxorubicin; Non Hodgkin lymphoma

Indexed keywords

ANTHRACYCLINE; ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; BRONCHOPNEUMONIA; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CARDIOMYOPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ELDERLY CARE; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; FRAIL ELDERLY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MALE; MULTIPLE CYCLE TREATMENT; MYASTHENIA GRAVIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PEPTIC ULCER; PILOT STUDY; PRIORITY JOURNAL; RHEUMATIC POLYMYALGIA; SIDE EFFECT; VOMITING;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FRAIL ELDERLY; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PILOT PROJECTS; PREDNISONE; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VINCRISTINE;

EID: 46749125451     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802043853     Document Type: Article

References (28)

1. Brincker, H., Pedersen, N. T., Bendix-Hansen, K. and Johansen, P. (2000) Non-Hodgkin's lymphoma subtypes over time in an unselected population of 646 patients: A study of clinico-pathological data and incidence based on a review using the REAL-classification. Leuk Lymphoma, 39, pp. 531-541.
2. Devesa, S. S. and Fears, T. (1992) Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res, 52, pp. 5432-5440.
3. Cartwright, R., Brincker, H., Carli, P. M., Clayden, D., Coebergh, J. W. Jack, A. et al. (1999) The rise in incidence of lymphomas in Europe 1985-1992. Eur J Cancer, 35, pp. 627-633.
4. Muller, A., Ihorst, G., Mertelsmann, R. and Engelhardt, M. (1999) Epidemiology of non-Hodgkin's lymphoma (NHL): Trends, geographic distribution and etiology. Ann Haematol, 84, pp. 1-12.
5. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med, 329, pp. 987-994.
6. The Non-Hodgkin's Lymphoma Classification Project (1997) Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. Ann Oncol, 8, pp. 973-978.
7. Bastion, Y., Blay, J. Y., Divine, M., Brice, P., Bordessoule, D. and Sebban, C. (1997) Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment, and survival-a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol, 15, pp. 2945-2953.
8. Vose, J. M., Armitage, J. O., Weisenburger, D. D., Bierman, P. J., Sorensen, S. and Hutchins, M. (1988) The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol, 6, pp. 1838-1844.
9. Fisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M. and Mize, E. M. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med, 328, pp. 1002-1006.
10. Gordon, L. I., Harrington, D., Andersen, J., Colgan, J., Glick, J. and Neiman, R. (1992) Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med, 327, pp. 1342-1349.
11. Jerkeman, M., Anderson, H., Cavallin-Ståhl, E., Dictor, M., Hagberg, H. Johnson, A. et al. (1999) CHOP versus MACOP-B in aggressive lymphoma - a Nordic Lymphoma Group randomised trial. Ann Oncol, 10, pp. 1079-1086.
12. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H. and Bouabdallah, R. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346, pp. 235-242.
13. Armitage, J. O. and Potter, J. F. (1984) Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: Increased complications with advancing age. J Am Geriatr Soc, 32, pp. 269-273.
14. Sonneveld, P., de Ridder, M., van der Lelie, H., Nieuwenhuis, K., Schouten, H. Mulder, A. et al. (1995) Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol, 13, pp. 2530-2539.
15. Meyer, R., Browman, G., Samosh, M., Benger, A., Bryant-Lukosius, D. Wilson, W. et al. (1995) Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol, 13, pp. 2386-2393.
16. Conley, B. A., Egorin, M. J., Whitacre, M. T., Carter, D. C., Zuhowski, E. G. and Van Echo, D. A. (1993) Phase I and pharmacokinetic trial of liposome encapsulated doxorubicin. Cancer Chemother Pharmacol, 33, pp. 107-112.
17. Cowens, J. W., Creaven, P. J., Greco, W. R., Brenner, D. E., Tung, Y. Ostro, M. et al. (1993) Initial clinical (Phase I) trial of Myocet (doxorubicin encapsulated in liposomes). Cancer Res, 53, pp. 2796-2802.
18. Ostro, M. J. (1989) Liposomes: From the bench to the marketplace-doxorubicin as an example. Liposomes in the Therapy of Infectious Diseases and Cancer, pp. 155-163. New York, Alan Liss
19. Mayer, L. D., Bally, M. B., Cullis, P. R., Wilson, S. L. and Emerman, J. T. (1990) Comparison of free and liposome-encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett, 53, pp. 183-190.
20. Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J. Guthrie, T. et al. (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol, 19, pp. 1444-1454.
21. Balducci, L. and Extermann, M. (2000) Management of cancer in the older person: A practical approach. Oncologist, 5, pp. 224-237.
22. Cheson, B. D., Horning, S. J. and Coiffier, B. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol, 17, pp. 1244-1253.
23. Fleming, T. R. (1982) One-sample multiple testing procedure for Phase II clinical trials. Biometrics, 38, pp. 143-151.
24. Harris, N. L., Jaffe, E. S. and Stein, H. (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood, 84, pp. 1361-1392.
25. Carbone, P. P., Kaplan, H. S. and Musshoff, K. (1971) Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res, 31, pp. 1860-1861.
26. Levine, A. M., Tulpule, A., Espina, B., Sherrod, A., Boswell, W. D. Lieberman, R. D. et al. (2004) Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: Results of therapy and correlates of response. J Clin Oncol, 22, pp. 2662-2670.
27. Tulpule, A., Espina, B. M., Berman, N., Buchanan, L. H., Smith, D. L. Sherrod, A. et al. (2006) Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. Clin Lymphoma Myeloma, 7, pp. 59-64.
28. Rigacci, L., Mappa, S., Nassi, L., Alterini, R., Carrai, V., Bernardi, F. and Bosi, A. (2007) Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. Hematol Oncol, 25, pp. 198-203.